Manipal Health Enterprises files RHP for Rs 8,000 crore fresh issue

The Development

Manipal Health Enterprises Limited has filed its red herring prospectus with the Securities and Exchange Board of India, placing one of the year's largest mainboard hospital offers on the official record. The red herring prospectus filed with SEBI, dated July 23, 2026, sets out a fresh issue of equity shares aggregating up to Rs 8,000 crore together with an offer for sale of up to 21,613,834 equity shares of face value Rs 2 each by seven selling shareholders. Per the RHP, the shares are proposed to be listed on the National Stock Exchange, the designated stock exchange for the offer, and BSE.

The offer was structured as a three-day book-built issue. Per the RHP, anchor investor allocation was scheduled for July 28, 2026, the bid and offer period opened on July 29 and closed on July 31, 2026, with the UPI mandate cut-off at 5:00 p.m. on the closing day. With bidding concluded, the registrar, KFin Technologies Limited, moves to finalise the basis of allotment before the shares are credited and listed. The milestone was surfaced through primary-market coverage aggregated on Google News. This being Manipal's first public issue, the RHP carries SEBI's standard caution that the shares have "neither been recommended, nor approved" by the regulator.

The Company

Manipal Health Enterprises operates a pan-India network of multispecialty hospitals delivering outpatient services alongside complex tertiary and quaternary care. The company describes itself as "the largest pan-India multispecialty hospital network by bed capacity" as of March 31, 2026, citing the CRISIL Report referenced in the RHP. It focuses on cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences, which the offer document groups under the label "CONGO-R". The company discloses that it served 7.63 million patients across its network in Fiscal 2026 and employed 24,240 people, with hospitals trading under the Manipal Hospitals brand from a Bengaluru base.

The headline financials are drawn from the restated consolidated information in the RHP. The company discloses revenue from operations of Rs 10,335.75 crore in Fiscal 2026, up from Rs 8,242.25 crore in Fiscal 2025 and Rs 6,171.63 crore in Fiscal 2024. Profit for the year was Rs 916.52 crore in Fiscal 2026, lower than the Rs 1,081.67 crore reported in Fiscal 2025 and above Fiscal 2024's Rs 533.20 crore. Per the RHP, total borrowings stood at Rs 10,553.43 crore as at March 31, 2026, up from Rs 4,766.83 crore a year earlier, and return on net worth was 10.57% in Fiscal 2026. The promoters are Dr. Ranjan Ramdas Pai and a group of investment holding entities; Dilip Jose Puthiyidathu is Managing Director and CEO.

The Offer Structure

Per the RHP, the offer combines a fresh issue of up to Rs 8,000 crore with an offer for sale of up to 21,613,834 equity shares. The company will not receive any proceeds from the offer for sale; each selling shareholder receives its portion net of expenses and taxes. The named sellers include Imperius Healthcare Investments Pte. Ltd. (up to 10,808,861 shares), Manipal Education and Medical Group India Private Limited (up to 6,792,002 shares) and TPG SG Magazine Pte. Ltd. (up to 2,329,667 shares), alongside four other investor shareholders.

The stated objects of the fresh issue are the repayment or prepayment of certain borrowings of the material subsidiary Manipal Hospitals Private Limited (an estimated Rs 5,552.76 crore), the acquisition of a minority stake in the stepdown subsidiary Sahyadri Hospitals Private Limited (an estimated Rs 574 crore), and general corporate purposes. The book running lead managers are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India, with KFin Technologies as registrar. The price band and lot size are set out in the separate price band advertisement and the exchange filings; the RHP leaves the offer price to be fixed through book building. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and prior reporting sits on the /news desk.

Risk Factors

Among the risk factors the company discloses, the RHP lists a heavy geographic concentration in Karnataka: 46.40%, 51.55% and 59.98% of revenue from operations in Fiscals 2026, 2025 and 2024 respectively came from its Karnataka hospitals. The offer document also flags specialty concentration, noting that 64.30%, 62.56% and 61.55% of gross inpatient revenue in those years came from the CONGO-R specialties, and dependence on non-cash payors, with insurance and third-party administrators accounting for 49.68% of gross inpatient revenue in Fiscal 2026.

The RHP further lists exposure to legal claims and regulatory action, including claims of alleged medical negligence. Two structural points are disclosed as risks: the offer is being made under Regulation 6(2) of the SEBI ICDR Regulations because the company had net tangible assets of less than Rs 30 million in Fiscal 2026 and does not meet the profitability route, and a portion of the net proceeds will repay non-convertible debentures held by DBS Bank Ltd, the parent of lead manager DBS Bank India, which is deemed an associate of promoter and selling shareholder Imperius Healthcare Investments. These are the company's own disclosures, not an assessment by this desk.

What Happens Next

The mechanics from here follow the standard book-built sequence. With the bid and offer period having closed on July 31, 2026, the registrar finalises the basis of allotment; application money blocked under the ASBA and UPI mechanisms is either debited against allotted shares or unblocked, and allotted shares are credited to demat accounts before trading begins. The shares are then listed on the NSE and BSE.

Category-wise subscription figures for qualified institutional buyers, non-institutional bidders and retail individual bidders are published by the exchanges from their bid data, and the final listing price will be recorded by the exchanges on the day of debut. Each is a matter of exchange record rather than a prediction of demand or price, and the RHP remains the operative document for the offer's terms.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges; read it directly before making any decision.

What is the size of the offer?

Per the RHP, the offer combines a fresh issue of equity shares aggregating up to Rs 8,000 crore with an offer for sale of up to 21,613,834 equity shares of face value Rs 2 each. The total offer value is finalised once the offer price is set through book building.

What are the objects of the fresh issue?

The RHP states the fresh-issue proceeds are for repaying or prepaying certain borrowings of subsidiary Manipal Hospitals Private Limited (an estimated Rs 5,552.76 crore), acquiring a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (an estimated Rs 574 crore), and general corporate purposes. The company receives nothing from the offer for sale.

When did the issue open and close?

Per the RHP, anchor allocation was scheduled for July 28, 2026, and the bid and offer period opened on July 29 and closed on July 31, 2026, with the UPI mandate cut-off at 5:00 p.m. on the closing day.

Where can I read the RHP?

The red herring prospectus is available on the SEBI website under Filings, Public Issues, and on the NSE and BSE websites, as well as the company's investor disclosures page. The abridged prospectus carries a summary of the salient features.

This report is based on the red herring prospectus filed with SEBI and the accompanying abridged prospectus on SEBI's public-issues record. It was surfaced via primary-market coverage aggregated on Google News.